Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2015-05-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
对外投资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about an external investment and related party transaction by the company 中源协和细胞基因工程股份有限公司. It includes information about the investment amount, parties involved, risk disclosures, corporate governance approvals, and legal compliance. The content focuses on the company's investment activities and related party transactions rather than financial results, audit opinions, or management discussions of financial performance. It is not a financial report, earnings release, or regulatory certification. The document is a formal announcement of a corporate transaction involving capital investment and related party dealings, which fits the category of Capital/Financing Update (CAP). The document length is about 4718 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the best classification is CAP with high confidence.
2015-05-18 Chinese
独立董事关于公司对外投资暨关联交易的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on an external investment and related party transaction by the company. It discusses the approval of a board meeting resolution regarding the investment and confirms compliance with relevant regulations and governance rules. The content focuses on governance and compliance aspects of a specific transaction rather than financial results, audit, or general regulatory announcements. It is not a full report, earnings release, or proxy material. The document fits best under Board/Management Information (MANG) as it relates to board decisions and management opinions on corporate actions involving related party transactions.
2015-05-18 Chinese
重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring. It mentions the stock suspension due to the ongoing major asset reorganization and states that updates will be provided every five trading days. The content focuses on the status and progress of a significant corporate transaction rather than the full details of the transaction or financial results. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is short and does not contain financial statements or detailed reports, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of a report publication. Therefore, the best classification is Capital/Financing Update (CAP).
2015-05-18 Chinese
华英证券有限责任公司关于中源协和细胞基因工程股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易之独立财务顾问持续督导意见（2014年度）
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's continuous supervision opinion report related to a major asset restructuring involving issuance of shares and cash payment to purchase assets, along with fundraising and related party transactions. It references regulatory frameworks such as the Shanghai Stock Exchange listing rules, China Securities Regulatory Commission regulations, and includes detailed descriptions of the transaction, asset transfer, fundraising, performance commitments, management discussion and analysis, company governance, and strategic plans. The document is lengthy (over 14,000 characters) and contains substantive financial and operational information, not merely an announcement or certification. It is not a full annual report but a specialized advisory and supervisory report on a major asset restructuring transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset acquisitions funded by share issuance and cash payments. Therefore, the appropriate classification is CAP with high confidence.
2015-05-13 Chinese
华英证券有限责任公司关于中源协和细胞基因工程股份有限公司发行股份及支付现金购买资产暨关联交易重大资产重组2014年度业绩承诺实现情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's opinion on the performance of a major asset restructuring transaction involving share issuance and cash payment for asset acquisition, specifically focusing on the 2014 annual performance commitment fulfillment. It includes detailed terms of profit compensation, cash and share compensation mechanisms, and audit verification of the 2014 profit achievement. The document is not a full annual report or audit report but rather a specialized verification and opinion related to a major asset restructuring transaction and related performance commitments. It is not a brief announcement or a simple notification but a substantive report on the transaction and performance verification. This fits best under the category of Capital/Financing Update (CAP), as it relates to a significant financing and asset acquisition transaction with detailed financial and contractual terms and verification.
2015-05-13 Chinese
关于召开2014年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2014 Annual General Meeting (AGM) of the company, including the date, voting methods, meeting agenda, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather informs shareholders about the meeting and the items to be voted on, such as the 2014 annual report and financial budget. The document length is 3275 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R).
2015-05-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.